<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825305</url>
  </required_header>
  <id_info>
    <org_study_id>M49P8</org_study_id>
    <nct_id>NCT00825305</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)</brief_title>
  <official_title>A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study investigates the safety and immunogenicity (non-inferiority) of a Purified Chick
      Embryo Cell Vaccine (PCECV) administered in two different schedules (conventional versus
      abbreviated schedule) in healthy adults 18 to 50 years of age in China
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rabies Virus Neutralizing Antibody Concentrations on Day 14.</measure>
    <time_frame>14 days</time_frame>
    <description>Rabies virus neutralizing antibody concentrations of the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Reported a Local or Systemic Reaction After Any Vaccination</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>Specified local and systemic reactions were solicited for 7 days after each vaccination. Number of participants were calculated who reported a local or systemic reaction after any of the vaccinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rabies Virus Neutralizing Antibody Concentrations on Day 7 and Day 42.</measure>
    <time_frame>7 days and 42 days</time_frame>
    <description>Rabies virus neutralizing antibody concentrations the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants With Seroconversion (Rabies Virus Neutralizing Antibody Concentrations Equal and Above 0.5 IU/ml) on Days 7, 14 and 42.</measure>
    <time_frame>7 days, 14 days and 42 days</time_frame>
    <description>Percentages of participants with seroconversion (defined as rabies virus neutralizing antibody concentrations equal and above 0.5 IU/ml) on days 7, 14 and 42.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">825</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>Zagreb (2-1-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Essen (1-1-1-1-1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Abbreviated Zagreb 2-1-1 schedule</intervention_name>
    <description>Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.</description>
    <arm_group_label>Zagreb (2-1-1)</arm_group_label>
    <other_name>PCEC Rabies vaccine for human use</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Essen 1-1-1-1-1 schedule</intervention_name>
    <description>Subjects received the standard Essen regimen.</description>
    <arm_group_label>Essen (1-1-1-1-1)</arm_group_label>
    <other_name>PCEC Rabies vaccine for human use</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 18-50 years of age who:

          -  are in good health at the time of entry into the study as determined by medical
             history, physical examination and clinical judgment of the investigator;

          -  volunteer for the simulated post-exposure vaccination courses and blood draws;

          -  have given a written informed consent; informed consent must be obtained for all the
             subjects before enrolment in the study;

          -  are available for all the visits scheduled in the study.

        Exclusion Criteria:

          -  Subjects with the below criteria were excluded:

          -  pregnancy or unwillingness to practice acceptable contraception during participation
             in the study;

          -  a history of rabies immunization;

          -  a significant acute or chronic infectious disease that may impact the subject's safety
             and /or immunogenicity in the Investigators opinion at the time of enrolment;

          -  fever ≥ 38.0°C (axillary) or/and significant acute or chronic infection requiring
             systemic antibiotic or antiviral therapy within the past 7 days before enrolment;

          -  treatment with corticosteroids, immunosuppressive or antimalaria drugs during the two
             month period before enrolment;

          -  administration of any vaccine within the past 14 days before enrolment;

          -  known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;

          -  history of allergy to egg protein;

          -  known hypersensitivity to neomycin, tetracycline, amphotericin-B, or any other vaccine
             component;

          -  treatment with parenteral immunoglobulin preparation, blood products, and/or plasma
             derivatives within the past 3 months;

          -  mental condition rendering the subject unable to understand the nature, scope and
             consequences of the study;

          -  participation in any other investigational trial within the past 3 months before
             enrolment;

          -  planned surgery during the study period;

          -  intention to leave the area of the study site before the end of study period;

          -  any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objective.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jizhou City</city>
        <state>Hebei</state>
        <zip>053200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>January 25, 2010</results_first_submitted>
  <results_first_submitted_qc>April 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2010</results_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>prevention</keyword>
  <keyword>rabies</keyword>
  <keyword>Rabies disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled in November 2008 at 1 center in China.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were randomized, but one subject in the Zagreb (2-1-1) group was not vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abbreviated Zagreb (2-1-1)</title>
          <description>Abbreviated Zagreb vaccination schedule with 2 vaccinations at day 0, 1 vaccination at day 7 and 1 vaccination at day 21.</description>
        </group>
        <group group_id="P2">
          <title>Conventional Essen(1-1-1-1-1)</title>
          <description>Conventional Essen schedule with 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
                <participants group_id="P2" count="275"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="533"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate inclusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Can not be classified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abbreviated Zagreb (2-1-1)</title>
          <description>Abbreviated Zagreb vaccination schedule with 2 vaccinations at day 0, 1 vaccination at day 7 and 1 vaccination at day 21.</description>
        </group>
        <group group_id="B2">
          <title>Conventional Essen(1-1-1-1-1)</title>
          <description>Conventional Essen schedule with 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="549"/>
            <count group_id="B2" value="275"/>
            <count group_id="B3" value="824"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline measures are presented for safety population.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="7.14"/>
                    <measurement group_id="B2" value="39.33" spread="6.93"/>
                    <measurement group_id="B3" value="38.58" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline measures are presented for safety population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="323"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rabies Virus Neutralizing Antibody Concentrations on Day 14.</title>
        <description>Rabies virus neutralizing antibody concentrations of the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.</description>
        <time_frame>14 days</time_frame>
        <population>Due to the Chinese registration requirements, only a subset of subjects bloodsamples were drawn and immunogenicity was evaluated. The per protocol population of this subset was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abbreviated Zagreb (2-1-1)</title>
            <description>Abbreviated Zagreb vaccination schedule with 2 vaccinations at day 0, 1 vaccination at day 7 and 1 vaccination at day 21.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Essen(1-1-1-1-1)</title>
            <description>Conventional Essen schedule with 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Virus Neutralizing Antibody Concentrations on Day 14.</title>
          <description>Rabies virus neutralizing antibody concentrations of the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.</description>
          <population>Due to the Chinese registration requirements, only a subset of subjects bloodsamples were drawn and immunogenicity was evaluated. The per protocol population of this subset was analyzed.</population>
          <units>IU/mL</units>
          <param>Log Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.73" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.82" upper_limit="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis states that the Zagreb schedule is inferior to the Essen schedule in terms of day 14 antibody titers assuming no difference between the two schedules and the equivalence limit of 1.5 titer levels (log2).</non_inferiority_desc>
            <param_type>ratio of log2 mean</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Ratio of log2 mean (Zagreb/Essen) on day 14</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rabies Virus Neutralizing Antibody Concentrations on Day 7 and Day 42.</title>
        <description>Rabies virus neutralizing antibody concentrations the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.</description>
        <time_frame>7 days and 42 days</time_frame>
        <population>Due to the Chinese registration requirements, only a subset of subjects bloodsamples were drawn and immunogenicity was evaluated. The per protocol population of this subset was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abbreviated Zagreb (2-1-1)</title>
            <description>Abbreviated Zagreb vaccination schedule with 2 vaccinations at day 0, 1 vaccination at day 7 and 1 vaccination at day 21.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Essen(1-1-1-1-1)</title>
            <description>Conventional Essen schedule with 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Virus Neutralizing Antibody Concentrations on Day 7 and Day 42.</title>
          <description>Rabies virus neutralizing antibody concentrations the abbreviated Zagreb regimen compared with the conventional Essen regimen. Results are presented on log2 scale. For results on original geometric (multiplicative) scale please raise numbers to the basis of 2.</description>
          <population>Due to the Chinese registration requirements, only a subset of subjects bloodsamples were drawn and immunogenicity was evaluated. The per protocol population of this subset was analyzed.</population>
          <units>IU/ml</units>
          <param>Log Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 7 results</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.23" lower_limit="-3.6" upper_limit="-2.86"/>
                    <measurement group_id="O2" value="-3.02" lower_limit="-3.45" upper_limit="-2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 42 results</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.80" upper_limit="4.70"/>
                    <measurement group_id="O2" value="4.32" lower_limit="3.84" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis states that the Zagreb schedule is inferior to the Essen schedule in terms of day 7 antibody titers assuming no difference between the two schedules and the equivalence limit of 1.5 titer levels (log2).</non_inferiority_desc>
            <param_type>ratio of log2 mean (day7)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
            <estimate_desc>Ratio of log2 means (Zagreb/Essen) on day 7</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis states that the Zagreb schedule is inferior to the Essen schedule in terms of day 42 antibody titers assuming no difference between the two schedules and the equivalence limit of 1.5 titer levels (log2).</non_inferiority_desc>
            <param_type>ratio of log2 mean (day 42)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
            <estimate_desc>Ratio of log2 mean (Zagreb/(Essen) on day 42</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Reported a Local or Systemic Reaction After Any Vaccination</title>
        <description>Specified local and systemic reactions were solicited for 7 days after each vaccination. Number of participants were calculated who reported a local or systemic reaction after any of the vaccinations.</description>
        <time_frame>7 days after each vaccination</time_frame>
        <population>Safety was analyzed for the safety set. One enrolled subject was not vaccinated and not included in the safety set because of inappropriate inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Abbreviated Zagreb (2-1-1)</title>
            <description>Abbreviated Zagreb vaccination schedule with 2 vaccinations at day 0, 1 vaccination at day 7 and 1 vaccination at day 21.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Essen(1-1-1-1-1)</title>
            <description>Conventional Essen schedule with 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported a Local or Systemic Reaction After Any Vaccination</title>
          <description>Specified local and systemic reactions were solicited for 7 days after each vaccination. Number of participants were calculated who reported a local or systemic reaction after any of the vaccinations.</description>
          <population>Safety was analyzed for the safety set. One enrolled subject was not vaccinated and not included in the safety set because of inappropriate inclusion.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483"/>
                    <measurement group_id="O2" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥37.1°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants With Seroconversion (Rabies Virus Neutralizing Antibody Concentrations Equal and Above 0.5 IU/ml) on Days 7, 14 and 42.</title>
        <description>Percentages of participants with seroconversion (defined as rabies virus neutralizing antibody concentrations equal and above 0.5 IU/ml) on days 7, 14 and 42.</description>
        <time_frame>7 days, 14 days and 42 days</time_frame>
        <population>Due to the Chinese registration requirements, only a subset of subjects bloodsamples were drawn and immunogenicity was evaluated. The per protocol population of this subset was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abbreviated Zagreb (2-1-1)</title>
            <description>Abbreviated Zagreb vaccination schedule with 2 vaccinations at day 0, 1 vaccination at day 7 and 1 vaccination at day 21.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Essen(1-1-1-1-1)</title>
            <description>Conventional Essen schedule with 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants With Seroconversion (Rabies Virus Neutralizing Antibody Concentrations Equal and Above 0.5 IU/ml) on Days 7, 14 and 42.</title>
          <description>Percentages of participants with seroconversion (defined as rabies virus neutralizing antibody concentrations equal and above 0.5 IU/ml) on days 7, 14 and 42.</description>
          <population>Due to the Chinese registration requirements, only a subset of subjects bloodsamples were drawn and immunogenicity was evaluated. The per protocol population of this subset was analyzed.</population>
          <units>percentages of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.14" lower_limit="4.18" upper_limit="19.79"/>
                    <measurement group_id="O2" value="10.0" lower_limit="4.12" upper_limit="19.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.79" upper_limit="100"/>
                    <measurement group_id="O2" value="97.14" lower_limit="90.19" upper_limit="99.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.79" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="94.87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Any unsolicited adverse events were collected for 7 days after each vaccination, all serious adverse events were collected throughout the whole study period (beyond individual study participation, from 12 Nov 2008 to 12 Jan 2009).</time_frame>
      <desc>Subjects were instructed to report on a daily basis any adverse events and record them on a diary card.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abbreviated Zagreb (2-1-1)</title>
          <description>Abbreviated Zagreb vaccination schedule with 2 vaccinations at day 0, 1 vaccination at day 7 and 1 vaccination at day 21.</description>
        </group>
        <group group_id="E2">
          <title>Conventional Essen(1-1-1-1-1)</title>
          <description>Conventional Essen schedule with 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injury of soft tissue in the leg and shoulder</sub_title>
                <description>Safety was analyzed for the safety set. One enrolled subject in the abbreviated Zaghreb group was not vaccinated and not included in the safety set, because of inappropriate inclusion.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="549"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Safety was analyzed for the safety set. One enrolled subject in the abbreviated Zaghreb group was not vaccinated and not included in the safety set, because of inappropriate inclusion.</description>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="549"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegContactVacUS.nvdit@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

